Skip to main content
Fig. 4 | Translational Neurodegeneration

Fig. 4

From: An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

Fig. 4

Presence of anti-drug antibodies (ADA) does not negatively affect Treg populations or UPDRS motor scores. a Anti-sargramostim neutralizing serum antibody titers collected from peripheral blood of individual subjects. b Correlation of ADA titers with change in Treg frequency for all subjects. c Correlation of ADA titers with change in UPDRS Part III scores for all subjects. Correlations were determined using Pearson product-moment correlation coefficients, and P-values determined for correlation coefficients greater than 0.25. Best-fit lines were determined using linear regression

Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us